A review of current devices and a look at new technology: drug-eluting stents

References

• Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularizatioN. N. Engl. J. Med.346(23), 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med.349(14), 1315–1323 (2003).
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med.350(3), 221–231 (2004).
   PubMed Web of Science ®Google Scholar
• Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet369(9562), 667–678 (2007).
   PubMed Web of Science ®Google Scholar
• Farb A, Boam AB. Stent thrombosis redux – the FDA perspective. N. Engl. J. Med.356(10), 984–987 (2007).
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Colombo A et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation115(22), 2842–2847 (2007).
   PubMed Web of Science ®Google Scholar
• Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol.48(1), 193–202 (2006).
   PubMed Web of Science ®Google Scholar
• Guagliumi G, Farb A, Musumeci G et al. Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation107(9), 1340–1341 (2003).
   PubMed Web of Science ®Google Scholar
• Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation115(18), 2435–2441 (2007).
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Finn AV, Joner M et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation118(11), 1138–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Awata M, Kotani J, Uematsu M et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation116(8), 910–916 (2007).
   PubMed Web of Science ®Google Scholar
• Matsumoto D, Shite J, Shinke T et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur. Heart J.28(8), 961–967 (2007).
   PubMed Web of Science ®Google Scholar
• Kubo T, Imanishi T, Kitabata H et al. Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris a serial optical coherence tomography study. J. Am. Coll. Cardiol. Img1(4), 475–484 (2008).
   Web of Science ®Google Scholar
• Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation109(6), 701–705 (2004).
   PubMed Web of Science ®Google Scholar
• Nebeker JR, Virmani R, Bennett CL et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J. Am. Coll. Cardiol.47(1), 175–181 (2006).
   PubMed Web of Science ®Google Scholar
• Finn AV, Nakazawa G, Joner M et al. Vascular responses to drug-eluting stents: importance of delayed healing. Arterioscler. Thromb. Vasc. Biol.27(7), 1500–1510 (2007).
   PubMed Web of Science ®Google Scholar
• Ahmed DD, Sobczak SC, Yunginger JW. Occupational allergies caused by latex. Immunol. Allergy Clin. North Am.23(2), 205–219 (2003).
   PubMedGoogle Scholar
• Leggat PA, Kedjarune U. Toxicity of methyl methacrylate in dentistry. Int. Dent. J.53(3), 126–131 (2003).
   PubMed Web of Science ®Google Scholar
• Farb A, Heller PF, Shroff S et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation104(4), 473–479 (2001).
   PubMed Web of Science ®Google Scholar
• Beijk MA, Neumann FJ, Wiemer M et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowing (the SPIRIT FIRST trial). Eurointervention1, 266–272 (2005).
   PubMedGoogle Scholar
• Fajadet J, Wijns W, Laarman GJ et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation114(8), 798–806 (2006).
   PubMed Web of Science ®Google Scholar
• Stone GW, Midei M, Newman W et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA299(16), 1903–1913 (2008).
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Leon MB, Popma JJ et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol.48(12), 2440–2447 (2006).
   PubMed Web of Science ®Google Scholar
• Slottow TL, Steinberg DH, Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on patent foramen ovale closure devices. Circulation116(6), 677–682 (2007).
   PubMed Web of Science ®Google Scholar
• Meredith IT, Ormiston J, Whitbourn R et al. Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am. J. Cardiol.100(8B), M56–M61 (2007).
   Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Dirschinger J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation103(23), 2816–2821 (2001).
   PubMed Web of Science ®Google Scholar
• Pache J, Kastrati A, Mehilli J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J. Am. Coll. Cardiol.41(8), 1283–1288 (2003).
   PubMed Web of Science ®Google Scholar
• Joner M, Nakazawa G, Finn AV et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol.52(5), 333–342 (2008).
   PubMed Web of Science ®Google Scholar
• Revell PA, Braden M, Freeman MA. Review of the biological response to a novel bone cement containing poly(ethyl methacrylate) and N-butyl methacrylate. Biomaterials19(17), 1579–1586 (1998).
   PubMed Web of Science ®Google Scholar
• Barrows T. Degradable implant materials: a review of synthetic absorbable polymers and their applications. Clin. Mater.1, 233–257 (1986).
   Google Scholar
• Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials21(23), 2335–2346 (2000).
   PubMed Web of Science ®Google Scholar
• Pietrzak WS, Sarver DR, Verstynen ML. Bioabsorbable polymer science for the practicing surgeon. J. Craniofac. Surg.8(2), 87–91 (1997).
   PubMed Web of Science ®Google Scholar
• Pietrzak WS, Verstynen ML, Sarver DR. Bioabsorbable fixation devices: status for the craniomaxillofacial surgeon. J. Craniofac. Surg.8(2), 92–96 (1997).
   PubMedGoogle Scholar
• Chu CC. The effect of pH on the in vitro degradation of poly(glycolide lactide) copolymer absorbable sutures. J. Biomed. Mater. Res.16(2), 117–124 (1982).
   PubMed Web of Science ®Google Scholar
• de Feyter PJ, Vos J, Rensing BJ. Anti-restenosis trials. Curr. Interv. Cardiol. Rep.2(4), 326–331 (2000).
   PubMedGoogle Scholar
• Holmes DR Jr, Savage M, LaBlanche JM et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation106(10), 1243–1250 (2002).
   PubMed Web of Science ®Google Scholar
• Gallo R, Padurean A, Jayaraman T et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation99(16), 2164–2170 (1999).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kopia G, Hayashi S et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation104(10), 1188–1193 (2001).
   PubMed Web of Science ®Google Scholar
• Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation103(24), 2967–2972 (2001).
   PubMed Web of Science ®Google Scholar
• Tanner FC, Boehm M, Akyurek LM et al. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferatioN. Circulation101(17), 2022–2025 (2000).
   PubMedGoogle Scholar
• Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr. Cancer Drug Targets3(3), 193–203 (2003).
   PubMed Web of Science ®Google Scholar
• Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J. Am. Coll. Cardiol.24(5), 1398–1405 (1994).
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Barragan P et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J. Am. Coll. Cardiol.50(14), 1299–1304 (2007).
   PubMed Web of Science ®Google Scholar
• Aoki J, Abizaid AC, Serruys PW et al. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J. Am. Coll. Cardiol.46(9), 1670–1676 (2005).
   PubMed Web of Science ®Google Scholar
• Hofma SH, van der Giessen WJ, van Dalen BM et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur. Heart J.27(2), 166–170 (2006).
   PubMed Web of Science ®Google Scholar
• Togni M, Windecker S, Cocchia R et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol.46(2), 231–236 (2005).
   PubMed Web of Science ®Google Scholar
• Stahli BE, Camici GG, Steffel J et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ. Res.99(2), 149–155 (2006).
   PubMed Web of Science ®Google Scholar
• Steffel J, Latini RA, Akhmedov A et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation112(13), 2002–2011 (2005).
   PubMed Web of Science ®Google Scholar
• Muldowney JA 3rd, Stringham JR, Levy SE et al. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler. Thromb. Vasc. Biol.27(2), 400–406 (2007).
   PubMedGoogle Scholar
• Ostojic M, Sagic D, Beleslin B et al. First clinical comparison of Nobori–Biolimus A9 eluting stents with Cypher–SIROLIMUS eluting stents: NOBORI CORE nine months angiographic and one year clinical outcomes. Eurointervention3, 574–579 (2008).
   PubMedGoogle Scholar
• Grube E, Buellesfeld L. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev. Med. Devices3(6), 731–741 (2006).
   PubMed Web of Science ®Google Scholar
• Grube E, Hauptmann K, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of a biolimus A9 eluting stent with a biogradable polymer coating. Eurointervention1, 53–57 (2005).
   PubMedGoogle Scholar
• Donners MM, Daemen MJ, Cleutjens KB, Heeneman S. Inflammation and restenosis: implications for therapy. Ann. Med.35(7), 523–531 (2003).
   PubMed Web of Science ®Google Scholar
• Morice MC, Wijins W, DiMario C et al. Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents: the randomized JUPITER II trial. Eurointervention2, 45–52 (2006).
   PubMedGoogle Scholar
• Verheye S, Dawkins KD, Dens J et al. Safety and efficacy outcomes of dual pimecrolimus/paclitaxel drug delivery versus single drug delivery using conor reservoir technology: GENESIS trial six-month results. Presented at: SCAI-ACCi2 Education sessions. Chicago, IL, USA, 31 March 2008.
   Google Scholar
• Kolodgie FD, John M, Khurana C et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation106(10), 1195–1198 (2002).
   PubMed Web of Science ®Google Scholar
• Finn AV, Kolodgie FD, Harnek J et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation112(2), 270–278 (2005).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ruygrok P, Neuzner J et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. Eurointervention2, 286–294 (2006).
   PubMedGoogle Scholar
• Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J. Interv. Cardiol.19(5), 405–413 (2006).
   PubMedGoogle Scholar
• Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet372(9644), 1163–1173 (2008).
   PubMed Web of Science ®Google Scholar
• Mehilli J, Kastrati A, Wessely R et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation113(2), 273–279 (2006).
   PubMed Web of Science ®Google Scholar
• Wessely R, Hausleiter J, Michaelis C et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler. Thromb. Vasc. Biol.25(4), 748–753 (2005).
   PubMed Web of Science ®Google Scholar
• Aoki J, Serruys PW, van Beusekom H et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth–First In Man) Registry. J. Am. Coll. Cardiol.45(10), 1574–1579 (2005).
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Kolodgie FD, Parker S, Yoklavich M, Virmani R. Improved endothelial coverage of drug-eluting stents when overlapped with an endothelial progenitor cell capture stent (Abst). Presented at: SCAI-ACCi2 e-Poster sessions. Chicago, IL, USA, 29 March–1 April 2008.
   Google Scholar
• Tamai H, Igaki K, Kyo E et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation102(4), 399–404 (2000).
   PubMed Web of Science ®Google Scholar
• Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet371(9616), 899–907 (2008).
   PubMed Web of Science ®Google Scholar
• Serruys PW. The future of DES technology (presentation). Presented at: EuroPCR. Barcelona, Spain, 13–16 May 2008.
   Google Scholar